A detailed history of Geode Capital Management, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 4,012,053 shares of LYEL stock, worth $6.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,012,053
Previous 4,017,021 0.12%
Holding current value
$6.06 Million
Previous $8.96 Million 35.06%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$1.3 - $3.01 $6,458 - $14,953
-4,968 Reduced 0.12%
4,012,053 $5.82 Million
Q1 2024

May 13, 2024

BUY
$1.71 - $3.07 $136,237 - $244,589
79,671 Added 2.02%
4,017,021 $8.96 Million
Q4 2023

Feb 13, 2024

BUY
$1.39 - $2.35 $390,405 - $660,037
280,867 Added 7.68%
3,937,350 $7.64 Million
Q3 2023

Nov 13, 2023

BUY
$1.45 - $3.35 $406,949 - $940,194
280,655 Added 8.31%
3,656,483 $5.38 Million
Q2 2023

Aug 11, 2023

BUY
$1.89 - $3.86 $354,172 - $723,336
187,393 Added 5.88%
3,375,828 $10.7 Million
Q1 2023

May 15, 2023

BUY
$1.97 - $3.58 $268,767 - $488,419
136,430 Added 4.47%
3,188,435 $7.52 Million
Q4 2022

Feb 13, 2023

BUY
$2.78 - $8.09 $281,766 - $819,961
101,355 Added 3.44%
3,052,005 $10.6 Million
Q3 2022

Nov 14, 2022

BUY
$5.54 - $8.27 $5.95 Million - $8.89 Million
1,074,563 Added 57.28%
2,950,650 $21.6 Million
Q2 2022

Aug 12, 2022

BUY
$3.68 - $6.8 $1.55 Million - $2.87 Million
421,854 Added 29.01%
1,876,087 $12.2 Million
Q1 2022

May 13, 2022

BUY
$5.05 - $7.7 $4.52 Million - $6.9 Million
895,507 Added 160.28%
1,454,233 $7.34 Million
Q4 2021

Feb 11, 2022

BUY
$7.13 - $15.19 $191,376 - $407,714
26,841 Added 5.05%
558,726 $4.32 Million
Q3 2021

Nov 12, 2021

BUY
$11.0 - $17.95 $3.93 Million - $6.42 Million
357,465 Added 204.94%
531,885 $7.87 Million
Q2 2021

Aug 13, 2021

BUY
$15.99 - $16.89 $2.79 Million - $2.95 Million
174,420 New
174,420 $2.83 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $374M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.